



**REGISTERED OFFICE**

**GRANULES INDIA LTD.**, 2nd Floor, 3rd Block, My Home Hub,  
Madhapur, Hyderabad – 500 081, Telangana, INDIA.  
Tel: +91 40 30660000, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com  
CIN: L24110TG1991PLC012471

**Dated May 28, 2020**

National Stock Exchange of India Limited  
BSE Limited

NSE Symbol - Granules; BSE Code- 532482  
Dear Sir,

**Sub: Clarification on the presence of NDMA in the Company's Products**

US FDA recently released its finding on the presence of NDMA beyond acceptable limits in certain products. With regard to this Company is receiving requests from few of the investors for clarification on the status of presence of NDMA in Company's products.

With reference to this we would like to clarify that, Company has received communication from the US FDA stating that the US FDA has tested samples from a few lots of the Company's API and Finished dosage tablets and the results "did not detect NDMA." There is some ongoing activity between the Company and the US FDA and the Company notify the stock exchanges as communication progresses.

This is for your information and dissemination to the members.

Thanking you.

Yours faithfully,

**FOR, GRANULES INDIA LIMITED**

*Chaitanya*

**(CHAITANYA TUMMALA)  
COMPANY SECRETARY &  
COMPLIANCE OFFICER**